Cargando…

LATS1 and LATS2 suppress breast cancer progression by maintaining cell identity and metabolic state

Deregulated activity of LArge Tumor Suppressor (LATS) tumor suppressors has broad implications on cellular and tissue homeostasis. We examined the consequences of down-regulation of either LATS1 or LATS2 in breast cancer. Consistent with their proposed tumor suppressive roles, expression of both par...

Descripción completa

Detalles Bibliográficos
Autores principales: Furth, Noa, Pateras, Ioannis S, Rotkopf, Ron, Vlachou, Vassiliki, Rivkin, Irina, Schmitt, Ina, Bakaev, Deborah, Gershoni, Anat, Ainbinder, Elena, Leshkowitz, Dena, Johnson, Randy L, Gorgoulis, Vassilis G, Oren, Moshe, Aylon, Yael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Life Science Alliance LLC 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6238411/
https://www.ncbi.nlm.nih.gov/pubmed/30456386
http://dx.doi.org/10.26508/lsa.201800171
Descripción
Sumario:Deregulated activity of LArge Tumor Suppressor (LATS) tumor suppressors has broad implications on cellular and tissue homeostasis. We examined the consequences of down-regulation of either LATS1 or LATS2 in breast cancer. Consistent with their proposed tumor suppressive roles, expression of both paralogs was significantly down-regulated in human breast cancer, and loss of either paralog accelerated mammary tumorigenesis in mice. However, each paralog had a distinct impact on breast cancer. Thus, LATS2 depletion in luminal B tumors resulted in metabolic rewiring, with increased glycolysis and reduced peroxisome proliferator-activated receptor γ (PPARγ) signaling. Furthermore, pharmacological activation of PPARγ elicited LATS2-dependent death in luminal B-derived cells. In contrast, LATS1 depletion augmented cancer cell plasticity, skewing luminal B tumors towards increased expression of basal-like features, in association with increased resistance to hormone therapy. Hence, these two closely related paralogs play distinct roles in protection against breast cancer; tumors with reduced expression of either LATS1 or LATS2 may rewire signaling networks differently and thus respond differently to anticancer treatments.